Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,140.80
(
0.52%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,640.43
(
-0.27%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 117898

Wednesday, 01/25/2012 11:29:43 PM

Wednesday, January 25, 2012 11:29:43 PM

Post# of 257253
Confirmed on 4Q11 JNJ CC—Xarelto is no-go for VTE prevention in immobilized patients:

http://seekingalpha.com/article/321705-johnson-johnson-s-ceo-discusses-q4-2011-results-earnings-call-transcript

…after further consultation with the FDA, we have decided not to file an sNDA for the use of XARELTO in the medically ill population at this time, based on the results of the Magellan trial.

The at this time qualifier is, of course, perfunctory. This indication for Xarelto has effectively been dead for almost a year (#msg-61803303).

p.s. The analysis in paragraph B of #msg-69173426 assumes that the new oral anticoagulants make no headway against Lovenox in this indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now